Tumor Immunogenicity Biomarkers:
the Potential of Immunoscore IC® (CD8/PDL1) in Drug Development
About this webinar
The field of immunotherapy has witnessed remarkable advancements in recent years, revolutionizing the way we combat cancer. One of the key factors driving these breakthroughs is the identification and utilization of tumor immunogenicity biomarkers that enable Clinicians to tailor treatments for individual patients. This webinar will showcase the Immunoscore Immune Checkpoint (CD8/PDL1) assay. Experts will provide an in-depth review of the assay’s analytical performance, clinical relevance and efficacy, with a focus on metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).
Join this webinar to engage in a dynamic discussion with the featured speakers, addressing key questions, potential challenges and future directions in harnessing Immunoscore IC® for precision immunotherapy.
The Immunoscore IC is available for clinical research. It has not been cleared nor approved by the FDA and is not for use in diagnostic procedures. Immunoscore IC® is a French registered trademark of Veracyte
Who should attend
- Biomarker discovery
- Translational medicine
- Clinical development
- CDx development
What you will learn
- Technical review of Immunoscore IC® assay
- Analytical performance of Immunoscore IC®
- Promising results obtained with the Immunoscore IC® in clinical trials
Featured Speakers
Jérôme Galon, PhD
Jérôme Galon is the Director of Research at INSERM (French NIH) and Head of the Laboratory of Integrative Cancer Immunology in Paris, France. He is also Associate Director and Co-Founder of the European Academy of Tumor Immunology (EATI), a board member of the Society for Immunotherapy of Cancer (SITC) and Senior Vice President and Scientific Executive Director at Veracyte. His work on the comprehensive analysis of the tumor microenvironment led to the concept of cancer immune contexture.
Jérôme Galon pioneered Immunoscore and is the Principal Investigator of the Worldwide Immunoscore Consortium. He has been a consultant and/or served on the scientific advisory board of 28 biotech and pharmaceutical companies. His contributions have been recognized with numerous awards, including the William B Coley Award, USA (2010), the prestigious European Patent Office (EPO, EU) as European Inventor 2019 for Immunoscore®, the Senior Research Prize Jean Valade from the Fondation de France (2020) and on January 1st, 2020, he was appointed Knight of the Legion of Honour by presidential decree.
Jacques Fieschi, PhD
Having earned a PhD at CNRS in France and subsequently serving as a postdoctoral research fellow at CEA France, Jacques Fieschi embarked on a journey in the biotechnology industry. He held pivotal positions in research & development at Beckman Coulter, QIAGEN and more recently at HalioDx and Veracyte, where he played a crucial role in advancing cutting-edge technologies. Currently serving as the Vice President of Research & Development, Jacques continues to drive innovation, utilizing his extensive experience to push the boundaries of scientific discovery in the realm of immuno-oncology.
Partner for this event
Veracyte
Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte engages in strategic collaborations with biopharmaceutical researchers to provide comprehensive support for their cancer drug development initiatives. In doing so, we offer a wide range of tools and services to support translational research, clinical development, commercial access, and companion diagnostics.
Related webinars
More from Veracyte.
Enhanced Multiplex IHC Technology for Precision Oncology
A Tumor Microenvironment-Based Multiomics Analysis for Predictive Modelling
Improving Clinical Research in Oncology Using Immune Scoring Biomarkers & a Multi-omics Approach